Robeco Schweiz AG Has $56.81 Million Stake in Danaher Corporation $DHR

Robeco Schweiz AG decreased its position in Danaher Corporation (NYSE:DHR) by 13.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 286,522 shares of the conglomerate’s stock after selling 46,029 shares during the period. Danaher accounts for 1.3% of Robeco Schweiz AG’s portfolio, making the stock its 29th largest position. Robeco Schweiz AG’s holdings in Danaher were worth $56,806,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DHR. WFA of San Diego LLC purchased a new position in Danaher in the 2nd quarter worth about $26,000. Howard Hughes Medical Institute purchased a new stake in Danaher in the 2nd quarter worth approximately $27,000. TruNorth Capital Management LLC purchased a new position in Danaher during the third quarter worth approximately $28,000. Red Tortoise LLC raised its holdings in shares of Danaher by 175.0% during the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after acquiring an additional 98 shares during the last quarter. Finally, Tripletail Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter valued at approximately $31,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. KeyCorp restated an “overweight” rating on shares of Danaher in a research report on Thursday, December 18th. JPMorgan Chase & Co. boosted their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Evercore ISI restated an “outperform” rating and issued a $250.00 price target on shares of Danaher in a report on Monday, January 5th. Finally, Robert W. Baird set a $247.00 price objective on Danaher in a report on Wednesday, October 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $249.92.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Management raised FY‑2025 EPS guidance to $7.80 (vs. consensus ~$7.71), signalling confidence in near‑term earnings execution — a direct driver of upside expectations for the stock.
• Positive Sentiment: Danaher said Q4 revenue is tracking at the high end of guidance on strength in bioprocessing, indicating better-than-expected top-line momentum in a core growth area. Danaher Forecasts 4Q Revenue at High-End of Guidance on Bioprocessing Strength — Update
• Positive Sentiment: Equity research support: William Blair reiterated a Buy rating, arguing Danaher’s broad-based outperformance and growth justify a premium multiple — helps underpin investor confidence. Danaher: Buy Rating Reiterated on Broad-Based Outperformance and Premium-Justified Growth Outlook
• Positive Sentiment: Fund flows/manager positioning: Mar Vista flagged Danaher as a top contributor in Q4 for its U.S. Quality strategy, signalling institutional demand from quality-oriented funds. Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors
• Neutral Sentiment: Management commentary: Danaher presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for detail on strategy and outlook but largely reiterative; may not move the stock much unless new incremental news emerged. Danaher Corporation (DHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: CEO commentary scheduled/posted around Q4 results (PR release) — offers management color but is expected given the earnings cadence. Danaher CEO to Comment on Financial Performance
• Positive Sentiment: Zacks issued a positive estimate lift for Danaher earnings, adding analyst backing to the outlook. Zacks Research Issues Positive Estimate for Danaher Earnings
• Negative Sentiment: Insider selling flagged in recent reporting — raises near-term caution for some investors and can weigh on sentiment, particularly after a strong run-up. Possible Bearish Signals With Danaher Insiders Disposing Stock
• Negative Sentiment: High valuation (current PE ~48x) and recent gains increase the risk of profit-taking and short-term pullbacks despite positive fundamentals — likely a contributor to today’s weakness.

Danaher Stock Performance

Shares of DHR stock opened at $235.40 on Wednesday. The firm has a market cap of $166.27 billion, a P/E ratio of 48.54, a PEG ratio of 4.25 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The stock’s 50-day moving average is $226.70 and its two-hundred day moving average is $211.20.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the company earned $1.71 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.5%. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

Insiders Place Their Bets

In other news, Director Teri List sold 3,298 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director owned 20,762 shares of the company’s stock, valued at $4,702,593. This represents a 13.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 30,248 shares of company stock valued at $6,609,663. 11.20% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.